Hear how Jonathan Mill, PhD, group leader of the complex disease epigenetics group at the University of Exeter Medical School, is using genetic information to study the causes of molecular variation in the brain. By profiling genomic changes across critical periods of brain development, Mill and his team of researchers are leading the way toward a better understanding of neuropsychiatric diseases like Alzheimer’s, schizophrenia, and more.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. *Data calculations on file. Illumina, Inc., 2015.
Subscribe to the Illumina video channel